
NATURE . COM {
}
Title:
A phase II trial with rosiglitazone in liposarcoma patients | British Journal of Cancer
Description:
Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4 mg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2 – 16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {📚}
- Science
- Education
- Health & Fitness
Content Management System {📝}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of nature.com audience?
🌆 Monumental Traffic: 20M - 50M visitors per month
Based on our best estimate, this website will receive around 42,555,829 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {💸}
Display Ads {🎯}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {💰}
Display Ads {🎯}
$536,300 per month
Our estimates place Nature.com's monthly online earnings from display ads at $357,511 to $983,155.
Keywords {🔍}
patients, liposarcoma, pparγ, treatment, pubmed, article, google, scholar, cancer, cas, nature, rosiglitazone, clinical, liposarcomas, human, expression, patient, gene, differentiation, molecular, peroxisome, proliferatoractivated, receptor, tumour, cells, study, months, cell, tontonoz, gamma, analysis, data, troglitazone, spiegelman, leuven, level, fletcher, cookies, content, trial, genes, biological, adipsin, protein, myxoid, fusion, activation, performed, probe, privacy,
Topics {✒️}
nature portfolio privacy policy peroxisome proliferator-activated receptor-γ peroxisome-proliferator activated receptor-gamma advertising nature 363 nature soft-tissue sarcoma—gold standard social media peroxisome proliferator-activated receptors author information authors 0/ reprints lipid-activated transcription factor pax8-ppargamma1 fusion oncogene author correspondence tls-chop fusion protein ews-chop fusion transcript ultrasound-guided needle biopsy full size image permissions myxoid/round cell subtypes inhibit tumour growth myxoid/round cell liposarcomas high affinity ligand soft tissue simulators privacy 14 october 2003 rna-binding protein primary tumour sample dei tos utilising standard procedures explore content tissue-specific regulator journals search log solid tumor differentiation human colon cancer metastastic colon cancer van den bh human myxoid liposarcoma round cell liposarcoma cellular proliferation rates european economic area personal data meis-kindblom giant marker chromosomes chromosomal region 12q spring-driven device quantify mrna levels glyceraldehyde-3-phosphate dehydrogenase g-banded chromosomes
Schema {🗺️}
WebPage:
mainEntity:
headline:A phase II trial with rosiglitazone in liposarcoma patients
description:Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4âmg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2âââ16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
datePublished:2003-10-14T00:00:00Z
dateModified:2011-11-16T00:00:00Z
pageStart:1409
pageEnd:1412
sameAs:https://doi.org/10.1038/sj.bjc.6601306
keywords:
liposarcoma
rosiglitazone
PPARγ
Biomedicine
general
Cancer Research
Epidemiology
Molecular Medicine
Oncology
Drug Resistance
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig2_HTML.jpg
isPartOf:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:89
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:G Debrock
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:V Vanhentenrijk
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Sciot
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:M Debiec-Rychter
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Oyen
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:A Van Oosterom
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:A phase II trial with rosiglitazone in liposarcoma patients
description:Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4âmg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2âââ16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
datePublished:2003-10-14T00:00:00Z
dateModified:2011-11-16T00:00:00Z
pageStart:1409
pageEnd:1412
sameAs:https://doi.org/10.1038/sj.bjc.6601306
keywords:
liposarcoma
rosiglitazone
PPARγ
Biomedicine
general
Cancer Research
Epidemiology
Molecular Medicine
Oncology
Drug Resistance
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig2_HTML.jpg
isPartOf:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:89
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:G Debrock
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:V Vanhentenrijk
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Sciot
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:M Debiec-Rychter
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Oyen
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:A Van Oosterom
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:89
Organization:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:G Debrock
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
email:[email protected]
name:V Vanhentenrijk
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:R Sciot
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:M Debiec-Rychter
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:R Oyen
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:A Van Oosterom
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
PostalAddress:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
External Links {🔗}(83)
- What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11751490 each month?
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Prognostic%20impact%20of%20p53%20status%2C%20TLS-CHOP%20fusion%20transcript%20structure%2C%20and%20histological%20grade%20in%20myxoid%20liposarcoma%3A%20a%20molecular%20and%20clinicopathologic%20study%20of%2082%20cases&journal=Clin%20Cancer%20Res&volume=7&pages=3977-3987&publication_year=2001&author=Antonescu%2CCR&author=Tschernyavsky%2CSJ&author=Decuseara%2CR&author=Leung%2CDH&author=Woodruff%2CJM&author=Brennan%2CMF&author=Bridge%2CJA&author=Neff%2CJR&author=Goldblum%2CJR&author=Ladanyi%2CM
- What's the monthly income of https://doi.org/10.1016%2FS0024-3205%2802%2901510-2?
- Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12269390
- How much does http://scholar.google.com/scholar_lookup?&title=Apoptosis%20induced%20by%20activation%20of%20peroxisome-proliferator%20activated%20receptor-gamma%20is%20associated%20with%20Bcl-2%20and%20NF-kappaB%20in%20human%20colon%20cancer&journal=Life%20Sci&doi=10.1016%2FS0024-3205%2802%2901510-2&volume=70&pages=2631-2646&publication_year=2002&author=Chen%2CGG&author=Lee%2CJF&author=Wang%2CSH&author=Chan%2CUP&author=Ip%2CPC&author=Lau%2CWY generate monthly?
- How much does https://doi.org/10.1038%2F363640a0 pull in?
- How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8510758?
- How much profit is http://scholar.google.com/scholar_lookup?&title=Fusion%20of%20CHOP%20to%20a%20novel%20RNA-binding%20protein%20in%20human%20myxoid%20liposarcoma&journal=Nature&doi=10.1038%2F363640a0&volume=363&pages=640-644&publication_year=1993&author=Crozat%2CA&author=Aman%2CP&author=Mandahl%2CN&author=Ron%2CD making per month?
- How much revenue does https://doi.org/10.1053%2Fadpa.2000.8133 generate?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Liposarcoma%3A%20new%20entities%20and%20evolving%20concepts&journal=Ann%20Design%20Pathol&doi=10.1053%2Fadpa.2000.8133&volume=4&pages=252-266&publication_year=2000&author=Dei%20Tos%2CAP?
- What's https://doi.org/10.1073%2Fpnas.96.7.3951's gross income?
- What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10097144?
- How much income is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC22401 earning monthly?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Induction%20of%20solid%20tumor%20differentiation%20by%20the%20peroxisome%20proliferator-activated%20receptor-gamma%20ligand%20troglitazone%20in%20patients%20with%20liposarcoma&journal=Proc%20Natl%20Acad%20Sci%20USA&doi=10.1073%2Fpnas.96.7.3951&volume=96&pages=3951-3956&publication_year=1999&author=Demetri%2CGD&author=Fletcher%2CCD&author=Mueller%2CE&author=Sarraf%2CP&author=Naujoks%2CR&author=Campbell%2CN&author=Spiegelman%2CBM&author=Singer%2CS
- What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10954962?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Rosiglitazone&journal=Int%20J%20Clin%20Pract&volume=54&pages=333-337&publication_year=2000&author=Goldstein%2CBJ generate?
- Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11431375
- Find out how much http://scholar.google.com/scholar_lookup?&title=Mutational%20analysis%20of%20the%20peroxisome%20proliferator-activated%20receptor%20gamma%20gene%20in%20human%20malignancies&journal=Cancer%20Res&volume=61&pages=5307-5310&publication_year=2001&author=Ikezoe%2CT&author=Miller%2CCW&author=Kawano%2CS&author=Heaney%2CA&author=Williamson%2CEA&author=Hisatake%2CJ&author=Green%2CE&author=Hofmann%2CW&author=Taguchi%2CH&author=Koeffler%2CHP earns monthly
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7805034
- How much does http://scholar.google.com/scholar_lookup?&title=Translocation%20t%2812%3B16%29%28q13%3Bp11%29%20in%20myxoid%20liposarcoma%20and%20round%20cell%20liposarcoma%3A%20molecular%20and%20cytogenetic%20analysis&journal=Cancer%20Res&volume=55&pages=24-27&publication_year=1995&author=Knight%2CJC&author=Renwick%2CPJ&author=Cin%2CPD&author=Van%20den%2CBH&author=Fletcher%2CCD gross monthly?
- How much revenue does https://doi.org/10.1126%2Fscience.289.5483.1357 bring in?
- What's the revenue for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10958784?
- How much does http://scholar.google.com/scholar_lookup?&title=PAX8-PPARgamma1%20fusion%20oncogene%20in%20human%20thyroid%20carcinoma%20%5Bcorrected%5D&journal=Science&doi=10.1126%2Fscience.289.5483.1357&volume=289&pages=1357-1360&publication_year=2000&author=Kroll%2CTG&author=Sarraf%2CP&author=Pecciarini%2CL&author=Chen%2CCJ&author=Mueller%2CE&author=Spiegelman%2CBM&author=Fletcher%2CJA net monthly?
- What's https://doi.org/10.1097%2F00130404-200209000-00010's gross income?
- Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12416897 is on a monthly basis
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=A%20phase%20II%20study%20of%20troglitazone%2C%20an%20activator%20of%20the%20PPARgamma%20receptor%2C%20in%20patients%20with%20chemotherapy-resistant%20metastatic%20colorectal%20cancer&journal=Cancer%20J&doi=10.1097%2F00130404-200209000-00010&volume=8&pages=395-399&publication_year=2002&author=Kulke%2CMH&author=Demetri%2CGD&author=Sharpless%2CNE&author=Ryan%2CDP&author=Shivdasani%2CR&author=Clark%2CJS&author=Spiegelman%2CBM&author=Kim%2CH&author=Mayer%2CRJ&author=Fuchs%2CCS?
- How much money does https://doi.org/10.1074%2Fjbc.270.22.12953 make?
- How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7768881 earning monthly?
- See how much http://scholar.google.com/scholar_lookup?&title=An%20antidiabetic%20thiazolidinedione%20is%20a%20high%20affinity%20ligand%20for%20peroxisome%20proliferator-activated%20receptor%20gamma%20%28PPAR%20gamma%29&journal=J%20Biol%20Chem&doi=10.1074%2Fjbc.270.22.12953&volume=270&pages=12953-12956&publication_year=1995&author=Lehmann%2CJM&author=Moore%2CLB&author=Smith-Oliver%2CTA&author=Wilkison%2CWO&author=Willson%2CTM&author=Kliewer%2CSA makes per month
- How much does https://link.springer.com/doi/10.1007/s004280100423 bring in each month?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11561754 bring in?
- How much money does http://scholar.google.com/scholar_lookup?&title=Cytogenetic%20and%20molecular%20genetic%20analyses%20of%20liposarcoma%20and%20its%20soft%20tissue%20simulators%3A%20recognition%20of%20new%20variants%20and%20differential%20diagnosis&journal=Virchows%20Arch&doi=10.1007%2Fs004280100423&volume=439&pages=141-151&publication_year=2001&author=Meis-Kindblom%2CJM&author=Sjogren%2CH&author=Kindblom%2CLG&author=Peydro-Mellquist%2CA&author=Roijer%2CE&author=Aman%2CP&author=Stenman%2CG generate?
- Profit of http://scholar.google.com/scholar_lookup?&title=ISCN.%20An%20International%20System%20for%20Human%20Genetic%20Nomenclature&publication_year=1995&author=Mitelman%2CF
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11507074's financial summary
- How much does http://scholar.google.com/scholar_lookup?&title=Anticancer%20effects%20of%20thiazolidinediones%20are%20independent%20of%20peroxisome%20proliferator-activated%20receptor%20gamma%20and%20mediated%20by%20inhibition%20of%20translation%20initiation&journal=Cancer%20Res&volume=61&pages=6213-6218&publication_year=2001&author=Palakurthi%2CSS&author=Aktas%2CH&author=Grubissich%2CLM&author=Mortensen%2CRM&author=Halperin%2CJA make?
- Revenue of https://doi.org/10.1172%2FJCI0215634
- Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12370270
- How profitable is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151148?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=PPARgamma%20ligands%20inhibit%20primary%20tumor%20growth%20and%20metastasis%20by%20inhibiting%20angiogenesis&journal=J%20Clin%20Invest&doi=10.1172%2FJCI0215634&volume=110&pages=923-932&publication_year=2002&author=Panigrahy%2CD&author=Singer%2CS&author=Shen%2CLQ&author=Butterfield%2CCE&author=Freedman%2CDA&author=Chen%2CEJ&author=Moses%2CMA&author=Kilroy%2CS&author=Duensing%2CS&author=Fletcher%2CC&author=Fletcher%2CJA&author=Hlatky%2CL&author=Hahnfeldt%2CP&author=Folkman%2CJ&author=Kaipainen%2CA
- What's the monthly income of https://doi.org/10.1016%2FS1097-2765%2801%2980012-5?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10394368 produce monthly?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Loss-of-function%20mutations%20in%20PPAR%20gamma%20associated%20with%20human%20colon%20cancer&journal=Mol%20Cell&doi=10.1016%2FS1097-2765%2801%2980012-5&volume=3&pages=799-804&publication_year=1999&author=Sarraf%2CP&author=Mueller%2CE&author=Smith%2CWM&author=Wright%2CHM&author=Kum%2CJB&author=Aaltonen%2CLA&author=de%20la%2CCA&author=Spiegelman%2CBM&author=Eng%2CC
- How much does https://doi.org/10.1128%2FMCB.15.1.351 bring in each month?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7799943 generate?
- What is the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC231968?
- How much money does http://scholar.google.com/scholar_lookup?&title=PPAR%20gamma%202%20regulates%20adipose%20expression%20of%20the%20phosphoenolpyruvate%20carboxykinase%20gene&journal=Mol%20Cell%20Biol&doi=10.1128%2FMCB.15.1.351&volume=15&pages=351-357&publication_year=1995&author=Tontonoz%2CP&author=Hu%2CE&author=Devine%2CJ&author=Beale%2CEG&author=Spiegelman%2CBM make?
- Earnings of https://doi.org/10.1101%2Fgad.8.10.1224
- Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7926726
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=mPPAR%20gamma%202%3A%20tissue-specific%20regulator%20of%20an%20adipocyte%20enhancer&journal=Genes%20Dev&doi=10.1101%2Fgad.8.10.1224&volume=8&pages=1224-1234&publication_year=1994&author=Tontonoz%2CP&author=Hu%2CE&author=Graves%2CRA&author=Budavari%2CAI&author=Spiegelman%2CBM have monthly?
- Learn how profitable https://doi.org/10.1016%2F0092-8674%2894%2990006-X is on a monthly basis
- Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8001151
- http://scholar.google.com/scholar_lookup?&title=Stimulation%20of%20adipogenesis%20in%20fibroblasts%20by%20PPAR%20gamma%202%2C%20a%20lipid-activated%20transcription%20factor&journal=Cell&doi=10.1016%2F0092-8674%2894%2990006-X&volume=79&pages=1147-1156&publication_year=1994&author=Tontonoz%2CP&author=Hu%2CE&author=Spiegelman%2CBM income
- See how much https://doi.org/10.1073%2Fpnas.94.1.237 makes per month
- Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8990192
- How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC19300 produce monthly?
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Terminal%20differentiation%20of%20human%20liposarcoma%20cells%20induced%20by%20ligands%20for%20peroxisome%20proliferator-activated%20receptor%20gamma%20and%20the%20retinoid%20X%20receptor&journal=Proc%20Natl%20Acad%20Sci%20USA&doi=10.1073%2Fpnas.94.1.237&volume=94&pages=237-241&publication_year=1997&author=Tontonoz%2CP&author=Singer%2CS&author=Forman%2CBM&author=Sarraf%2CP&author=Fletcher%2CJA&author=Fletcher%2CCD&author=Brun%2CRP&author=Mueller%2CE&author=Altiok%2CS&author=Oppenheim%2CH&author=Evans%2CRM&author=Spiegelman%2CBM each month?
- How much profit does https://doi.org/10.1016%2FS0140-6736%2898%2910364-1 make?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10408502 generate?
- Profit of http://scholar.google.com/scholar_lookup?&title=Medical%20significance%20of%20peroxisome%20proliferator-activated%20receptors&journal=Lancet&doi=10.1016%2FS0140-6736%2898%2910364-1&volume=354&pages=141-148&publication_year=1999&author=Vamecq%2CJ&author=Latruffe%2CN
- What's the monthly income of https://citation-needed.springer.com/v2/references/10.1038/sj.bjc.6601306?format=refman&flavour=references?
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=G%20Debrock?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22G%20Debrock%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in monthly?
- Discover the revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=V%20Vanhentenrijk
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22V%20Vanhentenrijk%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's total income per month
- What are the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=R%20Sciot?
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22R%20Sciot%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M%20Debiec-Rychter generate?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M%20Debiec-Rychter%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earn?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=R%20Oyen bring in each month?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22R%20Oyen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A%20Van%20Oosterom pull in monthly?
- How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A%20Van%20Oosterom%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- What's the financial gain of https://s100.copyright.com/AppDispatchServlet?title=A%20phase%20II%20trial%20with%20rosiglitazone%20in%20liposarcoma%20patients&author=G%20Debrock%20et%20al&contentID=10.1038%2Fsj.bjc.6601306©right=The%20Author%28s%29&publication=0007-0920&publicationDate=2003-10-14&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC-SA?
- What's the financial gain of https://citation-needed.springer.com/v2/references/10.1038/sj.bjc.6601306?format=refman&flavour=citation?
- How much revenue does https://doi.org/10.1186/s12885-022-09379-6 bring in?
- What's the income generated by https://doi.org/10.1186/s12944-021-01593-8 each month?
- How much does https://doi.org/10.1186/s12885-016-2524-6 bring in each month?
- Revenue of https://doi.org/10.1038/nrclinonc.2014.26
- Earnings of https://doi.org/10.1038/nrc3214
- How much revenue does https://www.protocols.io/ produce monthly?
- How much revenue does https://www.natureindex.com/ generate?
- How much does http://www.naturechina.com make?
- What's the monthly income of https://www.natureasia.com/ja-jp?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Prism.js
- Zoom.js
Emails and Hosting {✉️}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk
CDN Services {📦}
- Crossref